-

Inari Medical, Inc. INVESTOR ALERT: Kirby McInerney LLP Alerts Inari Medical, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP alerts investors of the fast-approaching July 12, 2024 to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) securities during the period of March 10, 2021 to February 28, 2024, inclusive (“the Class Period”). The firm encourages investors to contact the firm by July 12, 2024, to be appointed lead plaintiff.

[Click here to learn more about the class action]

On February 28, 2024, Inari filed its Form 10-K for the fiscal year 2023 with the U.S. Securities and Exchange Commission (“SEC”). The Company revealed in this filing that it had received a civil investigative demand from the U.S. Department of Justice in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information and documents primarily relating to meals and consulting service payments provided to health care professionals. On this news, the price of Inari shares declined by $12.14 per share, or approximately 20.8%, from $58.26 per share on February 28, 2024, to close at $46.12 on February 29, 2024.

The complaint filed alleges that throughout the Class Period, Inari failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Company repeatedly touted Inari’s financial results and the success of its product sales but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers.

If you purchased or otherwise acquired Inari securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:NARI

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capital published a report that described Soleno’s only product, V...

CRMT Investors: Contact Kirby McInerney LLP About Investigation into Car-Mart, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Car-Mart, Inc. (“Car-Mart” or the “Company”) (NASDAQ:CRMT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 15, 2025, Car-Mart disclosed it would delay filing its annual report because “management identified the need t...

INSP INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Inspire Medical Systems, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE:INSP) investors of the January 5, 2026 deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Inspire securities between August 6, 2024 through August 4, 2025 (“the Class Period”). Follow the link below for more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is The Lawsuit About? The lawsuit allege...
Back to Newsroom